IMMUNOVANT INC. 2024-2025 Proxy Voting Records

Description as filed by funds: To elect as directors the three nominees named in the Company's proxy statement, each to hold office until our 2025 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Douglas Hughes

IMMUNOVANT INC.’s own tally for this item (“Elect Director: Douglas Hughes”): 97,129,496 for, 34,618,309 withheld, per its Form 8-K filed August 13, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 – Election of Directors Peter Salzmann, M.D., M.B.A., George Migausky and Douglas Hughes were each elected to serve as a member of Immunovant's Board of Directors (the "Board"), until the 2025 Annual Meeting of Stockholders and until his successor is duly elected and qualified, or until …”
Support: 74% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 75 asset managers below reported 8,395,082 for, 15,738,953 withheld, 2,336,986 abstained.

Showing the 25 largest of 75 asset managers. See all 75 in the interactive database.

Description as filed by funds: To elect as directors the three nominees named in the Company's proxy statement, each to hold office until our 2025 Annual Meeting of Stockholders and until their successors are duly elected and qualified: George Migausky

IMMUNOVANT INC.’s own tally for this item (“Elect Director: George Migausky”): 98,023,809 for, 33,723,996 withheld, per its Form 8-K filed August 13, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 – Election of Directors Peter Salzmann, M.D., M.B.A., George Migausky and Douglas Hughes were each elected to serve as a member of Immunovant's Board of Directors (the "Board"), until the 2025 Annual Meeting of Stockholders and until his successor is duly elected and qualified, or until …”
Support: 74% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 75 asset managers below reported 8,878,064 for, 15,255,971 withheld, 2,336,986 abstained.

Showing the 25 largest of 75 asset managers. See all 75 in the interactive database.

Description as filed by funds: To elect as directors the three nominees named in the Company's proxy statement, each to hold office until our 2025 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Peter Salzmann, M.D., M.B.A.

IMMUNOVANT INC.’s own tally for this item (“Elect Director: Peter Salzmann, M.D., M.B.A.”): 99,849,994 for, 31,897,811 withheld, per its Form 8-K filed August 13, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 76% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 75 asset managers below reported 7,627,159 for, 18,489,206 withheld, 354,656 abstained.

Showing the 25 largest of 75 asset managers. See all 75 in the interactive database.

Description as filed by funds: To approve, on a non-binding, advisory basis, the compensation of our named executive officers.

IMMUNOVANT INC.’s own tally for this item (“3. Approval, on a Non-Binding Advisory Basis, of the Compensation of Immunovant's Named Executive Officers”): 128,494,310 for, 3,249,170 against — passed, per its Form 8-K filed August 13, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3 - Approval, on a Non-Binding Advisory Basis, of the Compensation of Immunovant's Named Executive Officers The stockholders approved, on a non-binding advisory basis, the compensation of Immunovant's named executive officers, as disclosed in the Proxy Statement, including the compensation…”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 74 managers: 24,423,978 for, 1,998,948 against, 2,595 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 173 managers: 40,166,493 for, 2,687,602 against, 45,500 withheld. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending March 31, 2025.

IMMUNOVANT INC.’s own tally for this item (“2. Ratification of the Selection of Independent Registered Public Accounting Firm”): 138,241,628 for, 16,740 against — passed, per its Form 8-K filed August 13, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2 – Ratification of the Selection of Independent Registered Public Accounting Firm The stockholders ratified the selection by the Audit Committee of the Board of Ernst & Young LLP as Immunovant's independent registered public accounting firm for the fiscal year ending March 31, 2025, by th…”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 75 asset managers below reported 26,468,197 for, 229 against, 2,595 abstained.

Showing the 25 largest of 75 asset managers. See all 75 in the interactive database.